Cardiopulmonary Bypass Copolymer Surface
Modification Reduces Neither Blood Loss Nor
Transfusions in Coronary Artery Surgery

Abstract

Objective: Surface-modifying additives (SMA) have been suggested for improving cardiopulmonary bypass (CPB) circuit biocompatibility, potentially minimizing inflammatory complications and bleeding associated with CPB. The purpose of this prospective, randomized clinical study was to compare a novel copolymer surface-modified CPB circuit (SMARXT™; COBE® Cardiovascular) against the unmodified circuit. Methods: We randomized 122 patients with isolated coronary artery disease subjected to first-time surgery on CPB into either the SMA (n = 62) or the control group (n = 60). Exclusion criteria included renal insufficiency, liver disease, coagulopathy, anticoagulation therapy < 6 days preop, carotid artery stenosis > 70 %, and a history of stroke. We collected perioperative clinical data including drainage blood loss, transfusion requirements, duration of mechanical ventilation, and ICU stay. Platelet function was determined pre- and post-CPB. Results: SMA patients received 3.2 ± 0.9 (SD) grafts during 48 ± 16 min of aortic cross clamp and 91 ± 30 min CPB (Control: 3.0 ± 0.9 grafts; p = 0.33, 46 ± 14 min AXC; p = 0.36, and 84 ± 23 min CPB ; p = 0.14). In the SMA group, 23 patients (37 %) received red blood-cell transfusions, 9 patients (15 %) fresh frozen plasma, and 3 patients (5 %) received platelets (control: n = 27 [46 %], p = 0.44; n = 10 [17 %], p = 0.91; and n=4 [7 %], p = 0.71, respectively). Platelet count on CPB fell to the same level in both groups. In SMA patients, platelet function decreased from 94.2 ± 24.9 % pre-CPB to 79.5 ± 32.8 % post-CPB (p = 0.043) (control: from 87.7 ± 25.6 % to 69.4 ± 34.7 %; p = 0.001). Postoperative drainage blood loss, mechanical ventilation duration, and ICU stay were similar in both groups (p > 0.3). One patient of the control group was excluded due to surgical bleeding, and one SMA patient died. Conclusions: Our results show that the surface-modified CPB circuit decreased neither blood loss nor transfusions despite slightly better platelet function preservation compared to the unmodified circuit. This type of CPB circuit surface modification does not appear to improve clinical outcome in low-risk coronary artery surgery patients.

Key words

Cardiopulmonary bypass - Biocompatibility - Surface modification - Clinical outcome - Coronary bypass surgery

References

• 1 Hall R I, Smith M S, Rocker G. The systemic inflammatory response to cardiopulmonary bypass: pathophysiological, therapeutical, and pharmacological considerations.  Anesth Analg. 1997;  85 766-782
• 2 Edmunds LH L H. Inflammatory response to cardiopulmonary bypass.  Ann Thorac Surg. 1998;  66 (5) S12-16
• 3 Boyle E M, Pohlman T H, Johnson M C, Verrier E D. Endothelial cell injury in cardiovascular surgery: the systemic inflammatory response.  Ann Thorac Surg. 1997;  63 277-284
• 4 Asimakopoulos G. Mechanisms of the systemic inflammatory response.  Perfusion. 1999;  14 269-277
• 5 Fukotomie M, Kobayashi S, Niwaya K, Hamada Y, Kitamura S. Changes in platelet, granulocyte, and complement activation during cardiopulmonary bypass using heparin-coated equipment.  Artif Organs. 1996;  20 767-776
• 6 Sinci V, Kalaycioglu S, Gunaydin S, Imren Y, Gokgoz L, Soncul H, Ersoz A. Evaluation of heparin-coated circuits with full heparin dose strategy.  Ann Thorac Cardiovasc Surg. 1999;  5 156-163
• 7 Belboul A, al-Khaja N. Does heparin coating improve biocompatibility? A study on complement, blood cells and postoperative morbidity during cardiac surgery.  Perfusion. 1997;  12 385-391
• 8 Norton S B, Butt W W, Mullaly R J, Thuys C A, O'Connor E B, Byron K, Cochrane A D, Brizard C P, Karl T R. IL-6 and IL-8 levels after cardiopulmonary bypass are not affected by surface coating.  Ann Thorac Surg. 1999;  68 1751-1755
• 9 Defraigne J O, Pincemail J, Larbuisson R, Blaffart F, Limet R. Cytokine release and neutrophil activation are not prevented by heparin-coated circuits and aprotinin administration.  Ann Thorac Surg. 2000;  69 1084-1091
• 10 Fosse E, Thelin S, Svennevig J L, Jansen P, Mollnes T E, Hack E ,. et al . Duraflow II coating of cardiopulmonary bypass circuits reduces complement activation but does not affect the release of granulocyte enzymes: a European multicentre study.  Eur J Cardiothorac Surg. 1997;  11 320-327
• 11 Tsai C C, Deppisch R M, Forrestal L J, Ritzau G H, Oram A D, Gohl H J, Voorhees M E. Surface modifying additives for improved device-blood compatibility.  ASAIO J. 1994;  40 M 619-624
• 12 Ward R S, Riffle J S. Polysiloxane-polylactone block copolymers. (4663413). U. S. Patent 1987
• 13 Lovinger A J, Man B J, Padden F J, Mirau P A. Morphology and properties of polycaprolactone-poly(dimethyl siloxane)- polycaprolactone triblock copolymers.  J Polymer Sci. 1993;  31 115-123
• 14 Li J, Sly M K, Chao R, Constantinescu A, Kulkarni P V, Wians FH J r, Jessen M E, Eberhart R C. Transient adhesion of platelets in pump-oxygenator systems: influence of SMA and nitric oxide treatments.  J Biomater Sci Polym Ed. 1999;  10 235-246
• 15 Gu Y J, Boonstra P W, Rijnsburger A A, Haan J, van Oeveren W. Cardiopulmonary bypass circuit treated with surface-modifying additives: a clinical evaluation of blood compatibility.  Ann Thorac Surg. 1998;  65 1342-1347
• 16 Rubens F D, Labow R S, Lavallee G R, Watson M i, Robblee J A, Voorhees M E, Nathan H J. Hematologic evaluation of cardiopulmonary bypass circuits prepared with a novel block copolymer.  Ann Thorac Surg. 1999;  67 689-698
• 17 Despotis G J, Ikonomakou S, Levine V, Joiner-Maier D, Santoro S A, Joist J H. Effects of platelets and white blood cells and antiplatelet agent C7E3 (Reopro) on a new test of PAF procoagulant activity of whole blood.  Thromb Res. 1997;  86 205-219
• 18 Okano T, Aoyagi T, Kataoka K, Abe K, Sakurai Y, Shimada M, Shinohara I. Hydrophilic-hydrophobic microdomain surfaces having an ability to suppress platelet aggregation and their in vitro antithrombogenicity.  J Biomed Mater Res. 1986;  20 919-927
• 19 Colman R W. Surface-mediated defense reactions. The plasma contact activation system.  J Clin Invest. 1984;  73 1249-1253
• 20 Kappelmayer J, Bertiabei A, Edmunds LH J r, Edginton T S, Colman R W. Tissue factor is expressed on monocytes during simulated extracorporeal circulation.  CircRes. 1993;  72 1075-1081
• 21 Downing S W, Edmunds L H. Release of vasoactive substances during cardiopulmonary bypass.  Ann Thorac Surg. 1992;  54 1236-1243
• 22 Schonberger J P, van Oeveren W, Bredee J J, Everts P A, de Haan J, Wildevuur C R. Systemic blood activation during and after autotransfusion.  Ann Thorac Surg. 1994;  57 1256-1262
• 23 de Haan J, Boonstra P W, Monnink S H, Ebels T, van Oeveren W. Retransfusion of suctioned blood during cardiopulmonary bypass impairs hemostasis.  Ann Thorac Surg. 1995;  59 901-907
• 24 Edmunds L H. Invited Commmentary.  Ann Thorac Surg. 1999;  67 696-697